3rd biggest killer in EU in 2017 will be Pancreatic cancer

Image
ANI Washington D.C. [USA]
Last Updated : Nov 07 2016 | 1:22 PM IST

A study says that the deaths from pancreatic cancer will overtake breast cancer mortality rates in the European Union in 2017.

The findings, recently presented at UEG Week 2016, mean that pancreatic cancer will become the third leading cause of death from cancer in the EU behind lung and colorectal cancer.

Pancreatic cancer mortality rates are increasing in many countries across the EU and it is estimated that 91,500 deaths will occur from the disease next year, compared with 91,000 from breast cancer.

The research used time-linear prediction models to estimate mortality rates until 2025, when deaths from pancreatic cancer (111,500) across Europe are projected to have increased by almost 50 percent since 2010 (76,000)1. All countries included in the study show varying increases in pancreatic cancer mortality rates from 20 percent to a staggering 131 percent increase over the 15-year period.

Despite being the third biggest cancer killer, the incidence of pancreatic cancer across Europe is relatively low in comparison with colorectal, lung and breast cancer. This demonstrates the extremely poor outlook for patients that are diagnosed with the disease which, unlike many other cancers, has not changed in the last 40 years.

Research shows that the median five-year survival rate for pancreatic cancer across Europe is five percent and patients lose 98 percent of their healthy life expectancy at the point of diagnosis. Despite these alarming statistics, 64 percent of Europeans state that they know very little about pancreatic cancer and currently there is no feasible screening method.

Ahead of World Pancreatic Cancer Day on November 17, experts are calling for increased awareness of the disease to allow patients to be diagnosed in time for life-saving surgery. Professor Matthias Lohr, UEG pancreatic cancer specialist, explained, "Pancreatic cancer survival rate is lower than any other cancer. Consequently, it is absolutely vital that patients receive a diagnosis as early as possible to allow for surgery, which is currently the only potential for a cure".

"Members of the public as well as doctors are therefore advised to increase their knowledge of the signs for pancreatic cancer, which include new-onset diabetes, abdominal and back pain, a change in bowel habits and jaundice" added Professor Lohr.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 07 2016 | 1:22 PM IST

Next Story